The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 1, 2014, Pages 291-302

  Yu, Dan ^a   Tao, Bang Bao ^b   Yang, Yun Yun ^a   Du, Li Sha ^a   Yang, Shuang Shuang ^a   He, Xiao Jie ^a   Zhu, Yu Wen ^a   Yan, Jun Kai ^a   Yang, Qing ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; coptisine; indoleamine 2, 3 dioxygenase; indoleamine 2, 3 dioxygenase inhibitor; kynurenine pathway

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; BERBERINE; COPTISINE; DONEPEZIL; ENZYME INHIBITOR; INDAN DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL SURVIVAL; COGNITION; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PC12 CELL LINE; PHYSIOLOGY; PLAQUE, AMYLOID; RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BERBERINE; BRAIN; CELL SURVIVAL; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; INDANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MICE, TRANSGENIC; NOOTROPIC AGENTS; PC12 CELLS; PIPERIDINES; PLAQUE, AMYLOID; PRESENILIN-1; RATS;

EID: 84908670456     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140414     Document Type: Article

References (48)

1. Dale WE, Dang YH, Amiridze N, BrownOR(2000) Evidence that kynurenine pathway metabolites mediate hyperbaric oxygen-induced convulsions. Toxicol Lett 117, 37-43.
2. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimers disease hippocampus. Neuropath Appl Neurobiol 31, 395-404.
3. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D (2000) Tryptophan degradation and immune activation in Alzheimers disease. J Neural Transm 107, 343-353.
4. Cummings BJ, Pike CJ, Shankle R, CotmanCW(1996) Betaamyloid deposition and other measures of neuropathology predict cognitive status in Alzheimers disease. Neurobiol Aging 17, 921-933.
5. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Staniszewska M, Castellani RJ, Siedlak SL, Zhu XW, Lee HG, Perry G, Nagaraj RH, SmithMA(2010) Indoleamine 2,3-dioxygenase and 3-hydroxy-kynurenine modifications are found in the neuropathology of Alzheimers disease. Redox Rep 15, 161-168.
6. Kincses ZT, Toldi J, Vecsei L (2010) Kynurenines, neurodegeneration and Alzheimers disease. J Cell Mol Med 14, 2045-2054.
7. Walker DG, Link J, Lue L, Dalsing-Hernandez JE, Boyes BE (2006) Gene expression changes by amyloid beta peptidestimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukocyte Biol 79, 596-610.
8. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D (1999) Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 467, 133-138.
9. Baran H, Jellinger K, Deecke L (1999) Kynurenine metabolism in Alzheimers disease. J Neural Transm 106, 165-181.
10. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi M, Lackner A, Larsen SA, Leeonard HL, Markey SP, Martin A, Milstein S, Mouradian MM, Pranzatelli MR, Quearry BJ, Salazar A, Smith M, Strauss SE, Sunderland T, Swedo SW, Tourtellotte WW (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. Brain 115, 1249-1273.
11. Rogers J, Shen Y (2000) A perspective on inflammation in Alzheimers disease. Ann N Y Acad Sci 924, 132-135.
12. Kalaria RN (1999) Microglia and Alzheimers disease. Curr Opin Hematol 6, 15-24.
13. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S (2000) Activation of NADPH oxidase in Alzheimers disease brains. Biochem Biophys Res Commun 273, 5-9.
14. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. J Neurochem 78, 842-853.
15. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ (2003) Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 527, 105-112.
16. Heyes MP, Morrison PF (1997) Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J Neurochem 68, 280-288.
17. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ (2009) Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16, 77-86.
18. Ting KK, Brew BJ, Guillemin GJ (2009) Effect of quinolinic acid on human astrocytes morphology and functions: Implications in Alzheimers disease. J Neuroinflammation 6, 36.
19. Pierozan P, Zamoner A, Soska AK, de Lima BO, Reis KP, Zamboni F, Wajner M, Pessoa-Pureur R (2012) Signaling mechanisms downstream of quinolinic acid targeting the cytoskeleton of rat striatal neurons and astrocytes. Exp Neurol 233, 391-399.
20. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLOS One 4, e19823.
21. Takashima A (2008) Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy. J Alzheimers Dis 14, 371-375.
22. Jiang G, He Y, Fang R, Zhang G, Zeng J, Yi Y, Zhang S, Bu X, Cai S, Du J (2010) Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and posttranscriptional levels. Int J Biochem Cell B 42, 1840-1846.
23. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M (2011) The indoleamine- 2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLOS One 6, e6344.
24. Fujiwara M, Iwasaki K (1993) Toki-shakuyaku-san and orengedoku- to improve the disruption of spatial cognition induced by cerebral-ischemia and central cholinergic dysfunction in rats. Phytother Res 7, S60-S62.
25. Xu JH, Murakami Y, Matsumoto K, Tohda M, Watanabe H, Zhang SH, Yu GH, Shen J (2000) Protective effect of Orengedoku- to (Huang-Lian-Jie-Du-Tang) against impairment of learning and memory induced by transient cerebral ischemia in mice. J Ethnopharmacol 73, 405-413.
26. Fang Q, Zhan XP, Mo JL, Sun M (2004) The effect of huanglian jiedu tang on Alzheimers disease and its influence on cytokines. Zhongguo Zhong Yao Za Zhi 29, 575-578.
27. Zheng Y, Cheng X, Zhou W, Zhang Y (2008) Gene expression patterns of hippocampus and cerebral cortex of senescence-accelerated mouse treated with Huang-Lian-Jie- Du decoction. Neurosci Lett 439, 119-124.
28. Zhang GR, Cheng XR, Zhou WX, Zhang YX (2009) Agerelated expression of calcium/calmodulin-dependent protein kinase ii a in the hippocampus and cerebral cortex of senescence accelerated mouse prone/8 mice is modulated by anti-Alzheimers disease drugs. Neuroscience 159, 308-315.
29. Yu C, Zheng M, Kuang C, Huang W, Yang Q (2010) Orengedoku- to and its constituents with therapeutic potential in Alzheimers disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis 22, 257-266.
30. Wang L, Ye XL, Li XG, Chen Z, Chen XD, Gao Y, Zhao ZQ, Huang WW, Chen X, Yi J (2010) Metabolism, transformation and distribution of Coptis chinensis total alkaloids in rat. Zhongguo Zhong yao za zhi 35, 2017-2020.
31. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170.
32. Vorhees CV,Williams MT (2006) Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1, 848-858.
33. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43, 2424-2426.
34. Cady SG, Sono M (1991) 1-Methyl-dl-tryptophan, beta-(3- benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and beta-3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3- dioxygenase. Arch Biochem Biophys 291, 326-333.
35. Mandrekar-Colucci S, Landreth GE (2010) Microglia and inflammation in Alzheimers disease. CNS Neurol Disord Drug Targets 9, 156-167.
36. Li C, Zhao R, Gao K, Wei Z, Yin MY, Lau LT, Chui D, Yu ACH (2011) Astrocytes: Implications for neuroinflammatory pathogenesis of Alzheimers disease. Curr Alzheimer Res 8, 67-80.
37. Shearman MS, Ragan CI, Iversen LL (1994) Inhibition of pc12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell-death. Proc Natl Acad Sci U S A 91, 1470-1474.
38. Yamada A, Akimoto H, Kagawa S, Guillemin GJ, Takikawa O (2009) Proinflammatory cytokine interferongamma increases induction of indoleamine 2,3-dioxygenase in monocyticcells primed with amyloid beta peptide 1-42: Implications for the pathogenesis of Alzheimers disease. J Neurochem 110, 791-800.
39. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9, 1269-1274.
40. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10, 1088-1094.
41. OConnor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatr 14, 511-522.
42. Hirano H, Osawa E, Yamaoka Y, Yokoi T (2001) Gastricmucous membrane protection activity of coptisine derivatives. Biol Pharm Bull 24, 1277-1281.
43. Tanabe H, Suzuki H, Mizukami H, Inoue M (2005) Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells. Biochem Pharmacol 70, 1176-1184.
44. Yang Y, Ye XL, Li XG (2007) Antimicrobial effect of four alkaloids from Coptidis rhizome. Lishizhen Med Mater Med Res 18, 3013-3014.
45. Colombo ML, Bugatti C, Mossa A, Pescalli N, Piazzoni L, Pezzoni G, Menta E, Spinelli S, Johnson F, Gupta RC, Dasaradhi L (2001) Cytotoxicity evaluation of natural coptisine and synthesis of coptisine from berberine. Farmaco 56, 403-409.
46. Jung HA, Min B,Yokozawa T, Lee J, Kim YS, Choi JS (2009) Anti-Alzheimer and antioxidant activities of coptidis rhizoma alkaloids. Biol Pharm Bull 32, 1433-1438.
47. Zhou D, Liu AL, Du GH (2011) Inhibition of acetylcholinesterase and butyrylcholinesterase by coptisine and its derivatives. Chin J Pharmacol 25, 134-135.
48. Zwilling D, Huang S, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu H, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874.